|
| Press Releases |
|
 |
|
| Monday, February 23, 2026 |
|
|
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus |
| Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu. more info >> |
|
| Tuesday, February 17, 2026 |
|
|
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement |
| Bioxytran, Inc., a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements. more info >> |
|
| Wednesday, February 11, 2026 |
|
|
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran |
| Bioxytran, Inc. today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. more info >> |
|
| Monday, February 2, 2026 |
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics |
| Bioxytran, Inc., a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets. more info >> |
|
| Thursday, January 29, 2026 |
|
|
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline |
| Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company's strategic direction entering 2026. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
Feb 23, 2026 21:00: JST
|
|
|
10亿美金！英伟达、AMD持续重注"物理AI"
Feb 23, 2026 20:56 HKT/SGT
|
|
|
通用原子航空系統公司為MQ-9B開發遠程武器能力
Feb 23, 2026 20:10 HKT/SGT
|
|
|
通用原子航空系统公司为MQ-9B无人机开发远程武器能力
Feb 23, 2026 20:10 HKT/SGT
|
|
|
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B
Feb 23, 2026 20:10 HKT/SGT
|
|
|
通用原子航空系統公司與美國空軍在聯合自主演習中，透過F-22戰機與MQ-20無人機展示人機協同作戰能力
Feb 23, 2026 20:05 HKT/SGT
|
|
|
通用原子航空系统公司与美国空军在联合自主演习中展示F-22与MQ-20的有人-无人协同作战
Feb 23, 2026 20:05 HKT/SGT
|
|
|
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise
Feb 23, 2026 20:05 HKT/SGT
|
|
|
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
Feb 23, 2026 20:00 HKT/SGT
|
|
|
通用航空系統公司宣布推出YFQ-42A暗影梅林無人機
Feb 23, 2026 20:00 HKT/SGT
|
|
|
通用航空系统公司宣布推出YFQ-42A暗影梅林无人机
Feb 23, 2026 20:00 HKT/SGT
|
|
|
GA-ASI Announces YFQ-42A Dark Merlin
Feb 23, 2026 20:00 HKT/SGT
|
|
|
10億美金！英偉達、AMD持續重注「物理AI」
Feb 23, 2026 16:39 HKT/SGT
|
|
|
Shoucheng Expands Robotics Retail Footprint Ahead of Lunar New Year, Opens Three Beijing Stores
Feb 23, 2026 10:19 HKT/SGT
|
|
|
首程控股春節前密集落子 陶朱新造局三店聯動構建機器人線下生態網路
Feb 23, 2026 10:04 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
